Repligen (RGEN) to Release Earnings on Tuesday

Repligen (NASDAQ:RGEN) is projected to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of $0.42 per share for the quarter. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS.Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.04. The firm had revenue of $188.80 million for the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The company’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Down 0.7%

NASDAQ RGEN traded down $1.11 on Tuesday, reaching $149.06. 118,348 shares of the stock traded hands, compared to its average volume of 819,396. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a fifty day moving average price of $135.99 and a 200-day moving average price of $129.03. The company has a market cap of $8.39 billion, a price-to-earnings ratio of 7,453.53, a PEG ratio of 3.32 and a beta of 1.08. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52.

Analyst Ratings Changes

RGEN has been the topic of a number of analyst reports. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. HSBC assumed coverage on Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. Barclays boosted their target price on Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Finally, Stephens upgraded Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Insiders Place Their Bets

In other news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new position in shares of Repligen during the second quarter worth about $353,000. Tower Research Capital LLC TRC lifted its position in shares of Repligen by 14.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,448 shares of the biotechnology company’s stock valued at $180,000 after acquiring an additional 179 shares during the period. Captrust Financial Advisors lifted its position in shares of Repligen by 16.8% during the 2nd quarter. Captrust Financial Advisors now owns 6,566 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 946 shares during the period. Tidal Investments LLC raised its position in shares of Repligen by 13.7% during the 2nd quarter. Tidal Investments LLC now owns 5,160 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 621 shares during the last quarter. Finally, Sone Capital Management LLC raised its position in shares of Repligen by 136.9% during the 2nd quarter. Sone Capital Management LLC now owns 70,452 shares of the biotechnology company’s stock worth $8,763,000 after purchasing an additional 40,719 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.